Skip to content
Cyclacillin
Cyclapen-w (cyclacillin) is a small molecule pharmaceutical. Cyclacillin was first approved as Cyclapen-w on 1982-01-01. It is used to treat haemophilus infections, pneumococcal infections, respiratory tract infections, staphylococcal infections, and urinary tract infections in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
respiratory tract diseasesD012140
urogenital diseasesD000091642
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cyclacillin
Tradename
Company
Number
Date
Products
CYCLAPEN-WWyethN-050508 DISCN1982-01-01
3 products
CYCLAPEN-WWyethN-050509 DISCN1982-01-01
2 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
haemophilus infectionsEFO_1001127D006192
pneumococcal infectionsEFO_0000772D011008J13
respiratory tract infectionsD012141J06.9
staphylococcal infectionsD013203A49.01
urinary tract infectionsEFO_0003103D014552N39.0
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
195 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Vitamin b 12 deficiencyD014806EFO_0000734E53.822231522
AnemiaD000740EFO_0004272D64.9324512
Cardiovascular diseasesD002318EFO_0000319I982125
StrokeD020521EFO_0000712I63.92125
Myocardial infarctionD009203EFO_0000612I211214
SchizophreniaD012559EFO_0000692F2011214
NeoplasmsD009369C80123
VasoplegiaD056987213
Cognitive dysfunctionD060825G31.841113
Iron-deficiency anemiaD018798HP_0001891D50123
Show 17 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD002289185113
Coronary artery diseaseD003324I25.12114
T-cell lymphoma peripheralD016411C84.92314
Autistic disorderD001321EFO_0003758F84.02224
Covid-19D000086382U07.11113
Lung neoplasmsD008175C34.90313
Type 2 diabetes mellitusD003924EFO_0001360E111123
Urinary bladder neoplasmsD001749C67112
Transitional cell carcinomaD002295112
Chronic kidney failureD007676EFO_0003884N18.6112
Show 19 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetic neuropathiesD003929EFO_1000783145
Breast neoplasmsD001943EFO_0003869C501214
Systemic lupus erythematosusD008180EFO_0002690M32112
Head and neck neoplasmsD00625822
StomatitisD013280EFO_1001904K12.122
Nasopharyngeal neoplasmsD00930322
B-cell lymphomaD016393122
Coronary diseaseD00332711
Myocardial ischemiaD017202EFO_1001375I20-I2511
Heart diseasesD006331EFO_0003777I51.911
Show 19 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Carpal tunnel syndromeD002349EFO_0004143G56.0123
T-cell lymphoma cutaneousD016410C84.A22
ObesityD009765EFO_0001073E66.9112
Colorectal neoplasmsD01517911
Pancreatic ductal carcinomaD02144111
Pancreatic neoplasmsD010190EFO_0003860C2511
Triple negative breast neoplasmsD06472611
AdenocarcinomaD00023011
Sezary syndromeD012751C84.111
Primary cutaneous anaplastic large cell lymphomaD054446C86.611
Show 4 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients33
Diabetes mellitusD003920EFO_0000400E08-E1322
HyperhomocysteinemiaD02013822
Transient ischemic attackD002546EFO_0003764G45.922
Aphthous stomatitisD013281EFO_0003938K12.022
PregnancyD011247EFO_0002950Z33.122
Diabetes complicationsD04890911
Diabetic footD017719EFO_100145911
DeliriumD003693R41.011
NeutropeniaD009503D7011
Show 32 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCYCLACILLIN
INNciclacillin
Description
Cyclacillin is a penicillin. It has a role as an antibacterial drug.
Classification
Small molecule
Drug classpenicillins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC1(C)S[C@@H]2[C@H](NC(=O)C3(N)CCCCC3)C(=O)N2[C@H]1C(=O)O
Identifiers
PDB
CAS-ID3485-14-1
RxCUI2968
ChEMBL IDCHEMBL1200356
ChEBI ID31444
PubChem CID19003
DrugBankDB01000
UNII ID72ZJ154X86 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 102 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3,375 adverse events reported
View more details